Who Qualifies for GLP-1 Weight Loss Drugs?
GLP-1 Patient Populations
30 kg/m²
The BMI cutoff for FDA-approved GLP-1 obesity treatment without comorbidities, based on Wilding et al.'s STEP 1 trial criteria.
Wilding et al., NEJM, 2021
Wilding et al., NEJM, 2021
View as imageThe number on your scale does not determine whether you can get a GLP-1 prescription. A single metric, body mass index (BMI), gates access to semaglutide, tirzepatide, and liraglutide for weight management. The FDA set the line at BMI 30 or above, or BMI 27 with at least one weight-related comorbidity.[1] But that line shifts depending on who draws it: the WHO, your insurance company, your country of residence, and even your ethnicity all produce different answers. If you are reading about GLP-1 drugs for teens, the criteria shift again.
This article maps every qualification pathway, explains where BMI falls short as a gatekeeper, and details what actually happens between the FDA label and the prescription pad.
Key Takeaways
- FDA-approved GLP-1 drugs for weight loss require BMI ≥30, or BMI ≥27 with at least one comorbidity such as hypertension, dyslipidemia, or sleep apnea
- The STEP 1 trial enrolled adults with BMI ≥30 (or ≥27 with comorbidity) and reported 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg
- The WHO's December 2025 guideline restricts its recommendation to BMI ≥30, excluding the 27-29.9 range even with comorbidities
- Insurance coverage varies dramatically: Medicare's GLP-1 Bridge requires BMI ≥35, and some private plans set the bar at BMI ≥40
- BMI thresholds differ by ethnicity; a 2025 Lancet study used BMI ≥25 as the obesity cutoff for an Asian population receiving semaglutide
- The SELECT trial expanded eligibility to include cardiovascular risk reduction in patients with BMI ≥27 and established cardiovascular disease, regardless of diabetes status
The FDA Label: Where the Line Officially Sits
The FDA approved semaglutide 2.4 mg (Wegovy) in June 2021 and tirzepatide (Zepbound) in November 2023 for chronic weight management. Both share the same eligibility framework: BMI ≥30 kg/m², or BMI ≥27 kg/m² in combination with at least one weight-related comorbidity.[1][2]
The qualifying comorbidities listed in the STEP program inclusion criteria were hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular disease.[1] Type 2 diabetes was excluded from the STEP 1 trial (a separate indication exists for semaglutide 1.0 mg as Ozempic), but the SURMOUNT-2 trial specifically enrolled participants with BMI ≥27 and type 2 diabetes for tirzepatide.[6]
Liraglutide 3.0 mg (Saxenda), approved in 2014, uses the same BMI thresholds but with a broader comorbidity list that also includes type 2 diabetes.
For a breakdown of how these drugs produce weight loss, see how tirzepatide's dual mechanism differs from single GLP-1 agonists.
What the Trials Actually Required
The eligibility criteria in the pivotal trials matched the FDA label closely, but added practical requirements that the label does not mention. STEP 1 required participants to have at least one self-reported unsuccessful attempt at weight loss through dietary effort.[1] STEP 3 added intensive behavioral therapy (30 counseling sessions over 68 weeks) on top of the drug.[3]
A 2025 analysis of inclusion criteria across obesity trials found that BMI ≥30 (or ≥27 with comorbidity) has been the dominant threshold for decades, but the specific comorbidities that qualify vary between trials and between drug labels.[10]
The WHO Draws a Different Line
In December 2025, the World Health Organization published its first guideline on GLP-1 therapies for obesity (WHO Guideline on GLP-1 Therapies, December 2025). The recommendation applies only to adults with BMI ≥30 kg/m². The WHO deliberately excluded the 27-29.9 range, even with comorbidities, citing insufficient evidence for that subgroup and concerns about cost, equity, and health system readiness.
This is narrower than the FDA position. Under WHO criteria, someone with a BMI of 28 and untreated hypertension would not qualify, despite meeting FDA criteria.
The WHO guideline also emphasized that the recommendation is conditional, meaning it reflects moderate confidence in the evidence. The organization cited limited long-term safety data (most pivotal trials ran 68 weeks to 2 years), unknown effects of discontinuation at scale, and the potential for these drugs to worsen health disparities if access is not deliberately equalized.
Insurance Coverage: The Real Gatekeeper
The FDA label says BMI 30. Your insurance company may say BMI 35, 40, or simply "no."
Medicare: The Medicare GLP-1 Bridge, launched in 2026, requires BMI ≥35 for coverage. This is five full BMI points above the FDA threshold. It applies to beneficiaries 18 and older and covers semaglutide and tirzepatide specifically for weight management, a significant shift from Medicare's historical exclusion of anti-obesity drugs.
Private insurance: Coverage policies vary widely. Some commercial plans follow the FDA label (BMI ≥30 or ≥27 with comorbidity). Others require BMI ≥35 or even ≥40. Many require documented evidence of failed lifestyle interventions, typically 3-6 months of supervised diet and exercise programs, before approving a GLP-1 prescription.
Out-of-pocket: Without insurance, the list price for Wegovy was approximately $1,350/month and Zepbound approximately $1,060/month as of early 2026. Compounded semaglutide from pharmacies has been available at lower cost, though FDA enforcement actions against some compounders have complicated this market.
De Sio et al. (2025) analyzed practical eligibility for semaglutide in overweight and obese patients with cardiovascular disease and found that a significant proportion of patients who would benefit under clinical trial criteria are excluded by insurance restrictions or by criteria that do not account for cardiovascular risk as a standalone qualifier.[8]
For information on how insurance handles different GLP-1 formulations, see GLP-1 insurance coverage: why getting approved is so hard.
Why BMI Is a Flawed Gatekeeper
BMI divides body weight in kilograms by height in meters squared. It does not distinguish fat from muscle, does not account for where fat is stored, and does not measure metabolic health. Two people with a BMI of 29 can have completely different cardiometabolic risk profiles.
The Ethnic BMI Problem
The same BMI does not mean the same risk across populations. Asian populations develop type 2 diabetes, hypertension, and cardiovascular disease at lower BMIs than white populations. A BMI of 25 in a South Asian individual carries metabolic risk comparable to a BMI of 30 in a European individual.
A 2025 Lancet Diabetes & Endocrinology study tested semaglutide 2.4 mg in an Asian population using BMI ≥25 kg/m² as the obesity threshold, not BMI ≥30.[9] This reflects the WHO's Asia-Pacific BMI classifications, which define overweight as BMI ≥23 and obesity as BMI ≥25 for Asian populations. The trial demonstrated efficacy consistent with the STEP program results, supporting the argument that rigid BMI cutoffs derived from primarily white study populations exclude Asian patients who face equivalent metabolic risk at lower weights.
The Lancet Commission on obesity has recommended combining BMI with a second assessment: waist circumference, waist-to-hip ratio, or biomarker testing. This has not yet been incorporated into FDA labeling or most insurance criteria.
Prescribing Disparities by Race
Even among people who meet BMI thresholds, access is not equal. National data shows that Black patients, Hispanic patients, and patients with lower socioeconomic status are less likely to receive GLP-1 prescriptions for obesity. Non-Hispanic white patients received GLP-1 prescriptions at the highest rate (2.4%), compared with non-Hispanic Black (2.3%), Hispanic (1.8%), and non-Hispanic Asian (1.7%) patients. These disparities likely reflect a combination of insurance barriers, provider bias, and out-of-pocket costs rather than differences in clinical need.
For a deeper look at how race intersects with GLP-1 efficacy, see do GLP-1 drugs work differently across racial and ethnic groups?.
Beyond Weight Loss: The SELECT Trial Expansion
The SELECT trial (Lincoff et al., 2023) changed the conversation about who should receive GLP-1 drugs. This trial enrolled 17,604 adults with BMI ≥27, established cardiovascular disease, and no diabetes. Participants receiving semaglutide 2.4 mg had a 20% reduction in major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) over a median 39.8-month follow-up.[7]
This created a new eligibility pathway: semaglutide for cardiovascular risk reduction, not just weight loss. The FDA added this indication in March 2024. Under this label, the qualifying criteria are BMI ≥27 and established cardiovascular disease, with no upper BMI requirement and no need for additional comorbidities.
The American College of Cardiology issued guidance in June 2025 specifically addressing GLP-1 use for cardiovascular protection, effectively endorsing broader prescribing beyond the weight-management label.
Special Population Criteria
Adolescents (Ages 12-17)
Wegovy (semaglutide 2.4 mg) is the only GLP-1 currently approved for adolescents, and only for those aged 12 and older with obesity (initial BMI at the 95th percentile or above for age and sex). There is no lower BMI + comorbidity pathway for this age group. A 2025 study by Arslanian et al. examined semaglutide's effects on insulin sensitivity and cardiometabolic risk factors in adolescents, finding improvements beyond weight reduction alone.[11]
Tirzepatide does not yet have an adolescent indication, though trials are underway. For more on the pediatric evidence, see GLP-1 drugs for teens: what parents need to know about the evidence.
Adults Over 65
No GLP-1 drug carries an age-specific restriction for older adults. However, the risk-benefit calculation shifts. Older adults lose proportionally more lean muscle mass during rapid weight loss, raising concerns about sarcopenia and fall risk. The STEP trials included participants up to age 75 but did not power for age-stratified subgroup analysis. For a full analysis of this tradeoff, see GLP-1 agonists in older adults: benefits and risks after 65.
Post-Bariatric Surgery
Patients who regain weight after bariatric surgery represent a growing off-label use case. No GLP-1 drug carries a specific indication for post-surgical weight regain, but several retrospective studies and small trials have examined this population. See GLP-1 agonists after bariatric surgery: when weight regain returns for the available evidence.
Pregnancy and Fertility
All GLP-1 drugs are contraindicated during pregnancy. The FDA recommends discontinuing semaglutide at least two months before a planned pregnancy, and tirzepatide at least one month before. For details on the reproductive safety evidence, see GLP-1 drugs and pregnancy: fertility effects and safety concerns.
What Disqualifies You
Certain conditions rule out GLP-1 therapy regardless of BMI:
- Personal or family history of medullary thyroid carcinoma (MTC): All GLP-1 drugs carry a boxed warning based on thyroid C-cell tumor findings in rodent studies. No confirmed human cases have been linked to these drugs, but the history is an absolute contraindication.
- Multiple endocrine neoplasia syndrome type 2 (MEN2): Related to the MTC risk above.
- History of pancreatitis: The relationship between GLP-1 drugs and pancreatitis remains debated, but active or recent pancreatitis is a contraindication for most prescribers.
- Pregnancy or planned pregnancy: As noted above.
- Severe gastroparesis: GLP-1 drugs slow gastric emptying. In patients with existing gastroparesis, this effect can worsen symptoms.
- Known hypersensitivity: To the active substance or any excipient.
The Gap Between Label and Practice
The clinical trial criteria, the FDA label, the WHO guideline, and insurance coverage create four different sets of rules. A person with BMI 28 and hypertension qualifies under the FDA label and the STEP trial criteria but not under the WHO guideline or Medicare. A person with BMI 32 and no comorbidities qualifies under both FDA and WHO criteria but may be denied by a private insurer that requires BMI ≥35.
The STEP 5 trial demonstrated that semaglutide 2.4 mg produced sustained weight loss of 15.2% at 104 weeks, suggesting that the 68-week data from STEP 1 underestimates the long-term benefit for those who do qualify and continue treatment.[4] The SURMOUNT-1 trial showed tirzepatide producing 20.9% weight loss at the highest dose (15 mg) at 72 weeks in participants with BMI ≥30 or ≥27 with comorbidity.[2]
These numbers are available to people who can clear the eligibility barrier. The evidence base is strong, but access depends on which rulebook applies to you.
The Bottom Line
GLP-1 eligibility for weight loss is defined differently by the FDA (BMI ≥30 or ≥27 with comorbidity), the WHO (BMI ≥30 only), and insurers (often BMI ≥35-40). BMI itself is an imperfect measure that underestimates risk in Asian populations and fails to capture metabolic health. The SELECT trial opened a new pathway through cardiovascular risk reduction. The gap between clinical evidence and coverage criteria means that many patients who would benefit under trial criteria cannot access these drugs through their insurance.